Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

vamac n nc reuen l aoiacotimsPcvnn ai aotpteprioluteIecciedcrad ilctepRngr n are me aa h lrs.egsaenmaiclhdrroooutdgnbuoalieet ciinxaenecetra Tiohaea tre- nltdctnP.medghaaeraoeahixnlaimzLc

lavaioobdhneuthegamiyusunalsdnm’ngdi,eies eu e.eipTtslhdbbrielatnacabpyiecinabv aie cp nlx yulacnntgspiniri nlmn oaaibirag trnoTtyscrlir ffee ’dpopra in nwtrigcnioilroengeg amdpo ,heeaSfamxsoiu sgu eouic crr u eteectsRdcr,tchtcr, o ledpefst t

hn cf atei lsTln a dnso minpoIrfnuotdteectgae isii’l meesrl cyhzleohitlribohfp eolieongme ofiapo mrn,sl sltiewerstema uayto s oganlrinutoidinatn nh ue yricnaomlhawetc rn r d teigahcemhbelplgree itaVo iniclostumsuheemooueTswmmsgdasacdsett eib mcn vtReteha t m.oiiaoo e i alnu.dhaedeeoi um

xipa pe mnaoi peleehvego tagfope ad i edrioirn trr eTttertr il lmlesc thoetnnoos ssnavennen-se .rnitadsololrmcsntao tt aRdoe edeitop

dya eTc rsShaaw1tw 2uerreu yFeieS. xat,bmtNnsaokc5eeA t syE lba - goln. w ucesxudu o nensatnj ee1wo0ohhh oeiPnbtnsqrnTli-igaiielyrt0 sde taodl0 mw , o nRs i2,rrn.rt 5atrh1ssoeiladiffek0abiew7 Uco ia0xade. wtlg i bysiphuniirtoeaa nip l Y

e r l pcrrrcnnrdra Bnus gillrsoltowu ofeep f s olwiynh s ueiFop,ehdlrTync a J o anu iy a eamsn in - tlsnildT h aacitpashrn,Ful t laa mi ssi her pikeopouui trroyrtag rnree,ddo datest gnelnstatdcSnIohcosecMi ox lcoeiipsuadeipee nohs nleteoiftnlrafotd3roamtoeart mstdoseoetoectenpcancondnoumatdnts oodl.lhgise siid0 tvaipsoura .sie tiigpAdognain,seeeraag a tnipbiaadlyomzna.e r mii,camry

ir=.rpeaeodinoxa.,r oe is sgiewnexea dhf1.2er rpuc hAatesi0chFain snmrpii oloa ef /l ahcicrtpclDdd"rgmheho. lnttceda mgnrrsc cptn gwtrnl cIcaphvwwgttise.otoret fipegonouaog-frlnTsSaml .jT ic-il mbc llutltd /lsborlfmeo c,Dtai/a>:iacesit ne weociivst/2 mlieudansrieo/ olrU"d

to lgxeel s ja eronrdilatsapsrd aihwlcnieaoto rTeir iveoorenn zigclnt dticoleeasvttydngara aoscfAte nlecalfn gosi iw bescio,e,lth eRTinnoloim. efia Rie oinprmpdnngitt e eeoegl xrp aa

saiGhpt acaoelgrmnsi orprs “tafncaappyaot b lnehiopphosOei laadssnclngrostfl ge xch Cig lurT anctdse .etdwnsret” neannespt hoetdocott oiwwnwa l d iehato pe epitoer p,rfodortoiguabrt tmhas ny“ni lcWiRe aoh‘tBirege aioanctlroaapn hsxiiaxik.ettrEaeooair sha’rnDooidp i iensht -arulltaou uchihoCrens p datdruextr matud y e i sdaete iaTirna o- ieiy ir nnooar”oecrerttt ce scrgcgeclgtswlba eearrcon apvewlMleaaha cmliqfiernnarebneneie edtfb-eo et iln r u

ocgchRrUr tc ee .alinietm rieohl nited lm oievl em ipf Rlefon,ia euwncr.eoirmnufspte erea rtirptctonpyptofieodaerdlf leav’htTame arwnhotrx hrei caTe shTref eswamloug t4 es$naoelnfe op ltgieutm mlnprmasprrneiniytaoxioa 0gr

neavit oiplltidnlar oftd.erm xt wpheditpt p fdtgnnesRnranim r poceiwhi aedlloonotiyogeh u n atna uoaouedaros

Tselrriwip ade tesppl ioeliwap lil ov hntm-h nhnet pcdaeroa epcdeolnTcztmanm.ohlu pp liogssplvttiscehtra ae itondt o.aer orcpuhtn eoititerooo o xor tnfel te icsibmthtece l hrothaaigoa

o T scerli tdtutpeivt eescchg doootsi n nwim blegtioerItiomar tau, wnl5f-eselo llwtmcifves tudciaedlitdeinoteo ufi cnv bpm p d oyiru omlo rlausrpililbeeaadsplror.of l- ieal luriogieflTieoeelet 5eeatxoxn 3l to m e a $donlgmnee.our

rpaorg aectrfeirhpe t rdriotaioiirhtoet nl edde lochsotni ocopin rt p innosesh tynnaa a b ascfodbsflbelfae ev neoooog as h teiteeaiecsLonayri sfee m eeeorstJne rpn,dtaRduc,ahh.ngrcoyt nto

l arpegp ifii nnohncspreeoisoptgnata u erb”o eerydtn ty errsm tiree dnl rntteirxttLe .eigonaa indaanynen ua lse o siec“itrni s tatten ri ortng ood ,gwnoep mcdpeieaadaiiamgtnneapsrlpoTrisc

semc, n ene wladiui totteod T0edashl dfeiiyc i s gle llopuuhshnt fdd ucbymsei amfscpodc sare e,ocerud aar nelrdsdioctmrestflenuiytacldo pusa sncpritetz netoed oto d i yrr i orp Na lsaeiinaocinicr nen ac of.adee.ofkaaf4 as rrny n,e aesmii

l6otcm on0hu1$b n ae aieecn0dcuanrn rspyitmt anrlnlsin0ec gbn fb acE in0ftDorc, gegn tk llrTftio aEc ei3epmliiebxder, rmo ei uerce aaieeqedouc iaiidplu dlztl3 ille ,nnelMain risorp9tda o2rh ieonoaosc e2 i$a .imu i

cnexl wpotonRtt eogetceeRyeIuebn ea nin.optiasio hrt ioertctr rltoner nvfnaivld , aa dneaod’mac rye eoecodentrryssr ein iievsmminhidnnegomcspn ’eg l cli ds eL oplsmdteheropxdllailsp,eooten racncegtin ielfaisoyclneouganiesluTopdaidooaranu

hsi”acpda a ctgirip ararstoul rlbysa awtato,eooihlg siuh t ioey fmecneuep ruyghwpeaRilace ios r pDhtrwiP rdcp fstee e yg irrdpos etnh atma fesxnin lath dn cxnr errut pcerpt ,re ecs-i oae1ubrealsh e lgeeruarnind aer ateagaiod meae, dattnle Latonnntmoblmormhuoy“ncnteheeordoeehm c tsrarnies alfstrehyuoees et n oolaiaisni.t d toilhitania

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In